Business Wire

IL-EVOTIX

2.11.2021 10:02:06 CET | Business Wire | Press release

Share
Evotix on Mission to Reduce Workplace Accidents in Europe and USA

Every year over 5,000 people are killed in workplace accidents in the US and EU – a number that’s risen in the US over the last ten years1 - and blue-collar workers in the US are five times as likely to have accidents as their white-collar counterparts2 .

Evotix, an ESG business, formerly known as SHE Software and a world leader in environmental, health, safety and well-being software (EHS), announces today its mission to help organizations reduce these numbers through its investment in new staff, software, support and training services.

The business’ proposition is focussed on giving its clients ‘the confidence to transform’. For many organizations, changing the way they handle health and safety can be daunting because they don’t want to uproot established practices even if they are based on out-of-date processes and technologies. Evotix has the in-depth expertise in the latest technologies, especially those that improve and simplify the user experience, that enables organizations to implement the changes they – and their employees – need to make EHS simpler and safer.

Matthew Elson, CEO of Evotix, explains, “People, especially those that are less advantaged, have the right to work in a safer environment. Our business already helps protect the safety of over 3,000,000 employees worldwide and we’re determined to protect many, many more in the years to come.”

“Too many employees suffer workplace accidents or endure workplace related physical and mental health problems, causing issues not only for those individuals but for businesses and wider society. Many of these unfortunate situations would be avoidable if health and safety were embedded in the way the organization truly functions, supported by software featuring the latest user-friendly technologies. Engaging employees on safety issues needs to be simple, sustainable and tailored for the need of each individual organization and that’s what Evotix has been built to offer.”

“The introduction of the Evotix name is just one step on our journey. The SHE Software name has served us well during our early years, but we wanted a name that was both memorable and reflects our vision and evolved proposition. The Evotix name is a conflation of the key qualities that make us special – evolutionary technology, innovation and experience.”

Based in Chicago and London, over the past five years Evotix has grown by over 40% every year and now has over 130 staff across the US, Europe and Asia-Pacific. In the last two years the company has experienced its fastest ever growth and major customers include: GlaxoSmithKline, New Balance, Citrix and University of Cambridge.

SOLUTIONS FOR TOMORROW

Evotix focusses on promoting workplace health and safety by providing innovative and engaging technology that gets embedded in the everyday flow of activity.

Evotix provides a comprehensive solution covering all aspects of health and safety management.

The solution is online and mobile-first designed to be used quickly and easily on-the-spot. With Evotix, incidents can be reported and shared within minutes, actions can be tracked to completion and underlying trends can be analysed.

Understanding documents on a mobile phone can be challenging: many organizations have a percentage of their workforce who are illiterate. Evotix employs microlearning video and quizzes in the field to engage employees in understanding risk and following defined working methods.

Every organization is different so the software can be easily tailored and adapted as requirements evolve. Evotix is continually adding new innovation as technology evolves.

Matthew continues, “Our approach helps organizations and employees alike. For organizations, accidents and incidents are expensive, with direct costs including lost hours, damage, disruption and claims, and indirect costs including the impact on morale, reputation, stress and management distraction. “

“We believe employees deserve better. The risks associated with workplace accidents fall disproportionately on the most disadvantaged in society - gig economy workers, casual labourers. An organization that prioritises risk reduction for all its staff will perform better financially, operationally and reputationally. That’s where we are here to help.”

Dawn Hemmings at Citrix says, “I’ve partnered with Evotix for over five years at three different organisations. I have always valued them as a partner that cares as passionately about improving workplace safety as I do. That’s why, when I joined Citrix, one of my first actions was to call Evotix. We know that their vision to make EHS simpler, more intuitive and more engaging is aligned with ours and they have the capabilities and plans to make that vision a reality.”

ABOUT EVOTIX

Evotix is a global ESG technology company transforming the way employees engage in workplace health and safety. Its market leading solution, Assure, is used by more than 400 customers across a wide range of industries including manufacturing, food & drink, construction, utility services, transport & logistics, municipalities, healthcare, education and housing.

Customers include GlaxoSmithKline, New Balance, Citrix, Finsbury Foods, Eddie Stobart, Network Rail, Wacker Neuson, Euro Car Parts and University of Cambridge.

Evotix’s intuitive, mobile first application fosters worker participation, guiding frontline activities while capturing rich data to help prioritise safety and operational improvements and ensure compliance. Ease of deployment and resulting swift customer impact drive Evotix’s rapid multi-year growth.

Evotix has offices in Chicago, London, Manchester, Glasgow and Melbourne, and is backed by significant investors including Mercia Asset Management and Frog Capital.


1 Eurostat: Accidents at work; US Bureau of Labor Statistics: Fatal occupational injuries
2 US Bureau of Labor Statistics: Fatal occupational injuries

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye